Lifecare (LIFE) Company presentation summary

Market opportunity and growth drivers

• Addressable market for implantable CGMs projected at over USD 5 billion in Europe and North America by 2035, with CGMs as the fastest-growing diabetes tech segment at a 12.5% CAGR from 2022–2030.

• Diabetes remains a major global health crisis, with 600 million people affected and 12% of global health expenditure spent on diabetes in 2024.

• Broader adoption of CGMs is driven by new user segments, including nondiabetics and athletes, and regulatory milestones such as FDA clearances and new guidelines.

• Implantable CGMs are expected to reach 15%+ market penetration, with Lifecare targeting a 20–30% share and peak revenue potential exceeding USD 1 billion.

• Pet market offers a USD 1 billion opportunity, with a fast regulatory path and near-term revenue potential.

Product innovation and competitive advantage

• Lifecare’s Sencell implantable CGM offers 6+ months of calibration-free use, high accuracy (MARD <10%), and a miniaturized, frictionless design based on osmotic pressure.

• Sencell’s osmotic technology provides superior accuracy, stability, and resistance to interference from food, drinks, and medications.

• Annual cost is estimated at ~$4,000, competitive with existing solutions, and requires no daily calibration.

• Full control over design, production, and IP, with protection until 2038.

Commercialization strategy and financial outlook

• Capital-efficient, partner-driven B2B model enables rapid scale-up, with partners handling sales, marketing, and distribution.

• Automated manufacturing in Germany launching in 2026, with capacity for 130,000 implants and expansion planned.

• Key milestones: veterinary market launch in 2025, CE mark in 2026, and human market launch in 2027.

• Revenue expected from 2027, with projected annual revenue of $200m+ and EBITDA margin above 35% by 2030.

• Additional financing needs are closely tied to regulatory and commercialization milestones, with a lean operational structure and projected runway into H1 2026.